EZH2 and neoplasm: Previous studies have focused on discovering EZH2 inhibitors for targeted therapy (17, 18), however, our study provided a novel therapeutic avenue for developing an effective inhibitor to disrupt PRADX-EZH2 interaction, thus increasing the expression of TSGs and finally inhibiting tumor growth.